Bill > HB1430

This bill addresses off-label prescription drug use in Mississippi by preventing professional licensing boards from restricting medical practitioners' ability to prescribe medications for purposes not originally approved by the U.S. Food and Drug Administration (FDA). Specifically, the bill defines "off-label use" as prescribing drugs for indications, dosages, or dosage forms that have not received FDA approval, including compounded medications. The legislation prohibits the State Board of Medical Licensure from preventing physicians, the Mississippi Board of Nursing from preventing advanced practice registered nurses, and the State Board of Pharmacy from preventing pharmacists from prescribing or filling off-label prescriptions. Additionally, the bill specifically protects advanced practice registered nurses' ability to prescribe semaglutide (a medication typically used for diabetes and weight management) under any brand name or generic formula. The provisions of this bill will take effect on July 1, 2024, and aim to provide healthcare practitioners with more flexibility in treatment options by removing potential regulatory barriers to off-label prescription practices.

Health and Social Services

https://billstatus.ls.state.ms.us/2025/pdf/history/HB/HB1430.xml